{"title":"Tuberculosis infection in patients with rheumatic diseases under different treatments","authors":"Tianhui Liu , Hongxuan Yan , Mengqiu Gao","doi":"10.1016/j.jiph.2025.102703","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><div>To describe the clinical characteristics of the patients with rheumatic disease who develop tuberculosis(TB), this study investigated the clinical characteristics of patients with rheumatic diseases under different treatments.</div></div><div><h3>Method</h3><div>We collected clinical data of patients diagnosed with rheumatic diseases complicated with TB at our hospital from January 2009 to October 2022. The patients were divided into three groups based on medication treatments: the biologic Disease Modifying anti-rheumatic drugs(bDMARDs) group, the no-immunotherapy group, and the conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) group. A retrospective analysis was conducted on these three groups.</div></div><div><h3>Results</h3><div>We found that patients using bDMARDs were less likely to develop cavities than the other two groups but were more likely to have extrapulmonary tuberculosis(EPTB). Additionally, the majority of patients experienced a time interval of 6 months or less from starting bDMARDs to the diagnosis of TB. The clinical characteristics of TB infection in patients with rheumatic diseases vary under different treatments.</div></div><div><h3>Discussion</h3><div>Patients with rheumatic diseases exhibit distinct clinical characteristics under various treatment regimens, such as differences in the presentation and severity of TB infection.</div></div>","PeriodicalId":16087,"journal":{"name":"Journal of Infection and Public Health","volume":"18 5","pages":"Article 102703"},"PeriodicalIF":4.7000,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Infection and Public Health","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1876034125000528","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0
Abstract
Objective
To describe the clinical characteristics of the patients with rheumatic disease who develop tuberculosis(TB), this study investigated the clinical characteristics of patients with rheumatic diseases under different treatments.
Method
We collected clinical data of patients diagnosed with rheumatic diseases complicated with TB at our hospital from January 2009 to October 2022. The patients were divided into three groups based on medication treatments: the biologic Disease Modifying anti-rheumatic drugs(bDMARDs) group, the no-immunotherapy group, and the conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) group. A retrospective analysis was conducted on these three groups.
Results
We found that patients using bDMARDs were less likely to develop cavities than the other two groups but were more likely to have extrapulmonary tuberculosis(EPTB). Additionally, the majority of patients experienced a time interval of 6 months or less from starting bDMARDs to the diagnosis of TB. The clinical characteristics of TB infection in patients with rheumatic diseases vary under different treatments.
Discussion
Patients with rheumatic diseases exhibit distinct clinical characteristics under various treatment regimens, such as differences in the presentation and severity of TB infection.
期刊介绍:
The Journal of Infection and Public Health, first official journal of the Saudi Arabian Ministry of National Guard Health Affairs, King Saud Bin Abdulaziz University for Health Sciences and the Saudi Association for Public Health, aims to be the foremost scientific, peer-reviewed journal encompassing infection prevention and control, microbiology, infectious diseases, public health and the application of healthcare epidemiology to the evaluation of health outcomes. The point of view of the journal is that infection and public health are closely intertwined and that advances in one area will have positive consequences on the other.
The journal will be useful to all health professionals who are partners in the management of patients with communicable diseases, keeping them up to date. The journal is proud to have an international and diverse editorial board that will assist and facilitate the publication of articles that reflect a global view on infection control and public health, as well as emphasizing our focus on supporting the needs of public health practitioners.
It is our aim to improve healthcare by reducing risk of infection and related adverse outcomes by critical review, selection, and dissemination of new and relevant information in the field of infection control, public health and infectious diseases in all healthcare settings and the community.